摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(6-氨基嘌呤-9-基)氧乙氧基甲基膦酸 | 124076-74-0

中文名称
2-(6-氨基嘌呤-9-基)氧乙氧基甲基膦酸
中文别名
——
英文名称
BRL 47923
英文别名
9-(2-(Phosphonomethoxy)ethoxy)adenine;2-(6-aminopurin-9-yl)oxyethoxymethylphosphonic acid
2-(6-氨基嘌呤-9-基)氧乙氧基甲基膦酸化学式
CAS
124076-74-0
化学式
C8H12N5O5P
mdl
——
分子量
289.188
InChiKey
HRVFEVBDZIXIGY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    146
  • 氢给体数:
    3
  • 氢受体数:
    9

SDS

SDS:602ade383c33e93702f8176e9306d58b
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    特戊酸氯甲酯2-(6-氨基嘌呤-9-基)氧乙氧基甲基膦酸三乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以41%的产率得到9-<2-<methyoxy>ethoxy>adenine
    参考文献:
    名称:
    Serafinowska; Ashton; Bailey, Journal of Medicinal Chemistry, 1995, vol. 38, # 8, p. 1372 - 1379
    摘要:
    DOI:
  • 作为产物:
    描述:
    6-Chloro-9-[2-(diethoxyphosphorylmethoxy)ethoxy]purine 、 三甲基溴硅烷 以21%的产率得到
    参考文献:
    名称:
    DUCKWORTH, D. M.;HARNDEN, M. R.;PERKINS, R. M.;PLANTEROSE, D. N., NUCLEOSIDES AND NUCLEOTIDES, 10,(1991) N-3, C. 427-430
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES 4'-ALLÈNE-SUBSTITUÉS
    申请人:ENANTA PHARM INC
    公开号:WO2010030858A1
    公开(公告)日:2010-03-18
    The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: Formula (I) which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
    本发明揭示了化合物的结构式(I),或其β-L对映体,或药学上可接受的盐、酯、立体异构体、互变异构体、溶剂合物、前药或其组合物:结构式(I),其能够抑制、预防或治疗异常细胞增殖和/或病毒感染,特别是HIV、HCV或HBV。因此,本发明的化合物干扰病毒的复制周期,并且也可作为抗病毒剂使用,或干扰宿主细胞的生化过程,也可作为抗增殖剂使用。本发明还涉及包含上述化合物的药物组合物,用于治疗患有病毒感染和/或细胞增殖的受试者。该发明还涉及通过给患有病毒感染和/或细胞增殖的受试者使用包含本发明化合物的药物组合物来治疗病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物,包括这些化合物的药物组合物和治疗或预防需要此类化疗的受试者的病毒感染的方法。
  • NUCLEOSIDE PHOSPHONATE DERIVATIVES
    申请人:Or Yat Sun
    公开号:US20090274686A1
    公开(公告)日:2009-11-05
    The present invention discloses compounds of formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
    本发明揭示了化合物的公式(I)或(II),或其药学上可接受的盐、酯或前药:这些化合物抑制、预防或治疗异常细胞增殖和/或病毒感染,特别是HIV、HCV或HBV。因此,本发明的化合物干扰病毒的复制周期,同时也可用作抗病毒剂,或干扰宿主细胞的生化过程,同时也可用作抗增殖剂。本发明还涉及包含上述化合物的药物组合物,用于治疗患有病毒感染和/或细胞增殖的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物,包括含有这些化合物的药物组合物,以及用于治疗或预防受试者的病毒感染的方法。
  • INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE
    申请人:Karlsruher Institut fur Technologie
    公开号:US20210292353A1
    公开(公告)日:2021-09-23
    The present invention relates to inorganic-organic hybrid compounds for use in medicine or for use as medication, consisting of an inorganic metal cation and an organic platinum-containing cytostatic anion, in particular also a cisplatin derivative.
    本发明涉及用于医学或作为药物使用的无机-有机杂化化合物,包括无机金属阳离子和含有铂的细胞静止阴离子,特别是顺铂衍生物。
  • Novel phosphonic acid based prodrugs of PMEA and its analogues
    申请人:——
    公开号:US20030229225A1
    公开(公告)日:2003-12-11
    Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1 wherein: M and V are cis to one another and MPO 3 H 2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxy propyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine; V is selected from a group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, C1-C3 alkyl, CF 3 and OR 6 ; R6 is selected from the group consisting of C1-C3 alkyl, and CF 3 ; and pharmaceutically acceptable salts thereof.
    公式I的前药、它们的用途、它们的中间体以及它们的制造方法被描述:其中:M和V相对于彼此是顺式的,MPO3H2是从以下组中选择的膦酸,包括9-(2-膦甲氧基乙基)腺嘌呤,(R)-9-(2-膦甲氧基丙基)腺嘌呤,9-(2-膦甲氧基乙基)鸟嘌呤,9-(2-膦甲氧基乙氧基)腺嘌呤,9-(2-膦甲氧基乙基)-2,6-二氨基嘌呤,(S)-1-(3-羟基-2-膦甲氧基丙基)胞嘧啶,(S)-9-(3-羟基-2-膦甲氧基丙基)腺嘌呤,9-(3-羟基-2-膦甲氧基丙基)鸟嘌呤,以及(S)-9-(3-氟-2-膦甲氧基丙基)腺嘌呤;V从以下组中选择,包括苯基,2-吡啶基,3-吡啶基,4-吡啶基,2-呋喃基,3-呋喃基,2-噻吩基和3-噻吩基,所有这些基可选地被1-3个来自F、Cl、Br、C1-C3烷基、CF3和OR6的基替代;R6从C1-C3烷基和CF3的组中选择;以及其药学上可接受的盐。
  • 2'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES
    申请人:Wang Guoqiang
    公开号:US20130078217A1
    公开(公告)日:2013-03-28
    The present invention relates to 2′-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related β-D and β-L-nucleoside derivatives.
    本发明涉及通式(I)的2'-氯乙炔基取代核苷衍生物,以及包含这些化合物的药物组合物和治疗或预防HIV感染、HBV感染、HCV感染或异常细胞增殖的方法,包括给予这些化合物或组合物。此外,本发明还包括用于制备这些化合物的方法,以及相关的β-D和β-L-核苷衍生物。
查看更多